Yajing Zhang

No. 28 Fuxing Road
Beijing, 100853, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma.

Five-Year Follow-Up: Tandem CD19/CD20 CAR T Therapy Enduring Impact on Refractory/Relapsed Non-Hodgkin Lymphoma.

Journal: American journal of hematology

Published: December 01, 2025

Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.

Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial.

Journal: Nature communications

Published: November 02, 2025

Discovery, delineation, and therapeutic targeting of a hyper-translation pathway driving cytokine release syndrome.

Discovery, delineation, and therapeutic targeting of a hyper-translation pathway driving cytokine release syndrome.

Journal: Cell reports. Medicine

Published: April 23, 2025

BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review.

BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review.

Journal: Critical reviews in oncology/hematology

Published: September 22, 2024

IL-6 translation is a therapeutic target of human cytokine release syndrome.

IL-6 translation is a therapeutic target of human cytokine release syndrome.

Journal: The Journal of experimental medicine

Published: April 05, 2023

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.

Journal: Cancer biology & medicine

Published: March 02, 2023

Challenges and optimal strategies of CAR T therapy for hematological malignancies.

Challenges and optimal strategies of CAR T therapy for hematological malignancies.

Journal: Chinese medical journal

Published: February 27, 2023

Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies.

Identification of NOXA as a pivotal regulator of resistance to CAR T-cell therapy in B-cell malignancies.

Journal: Signal transduction and targeted therapy

Published: November 20, 2021

Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy.

Correction to: Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy.

Journal: Journal of hematology & oncology

Published: September 24, 2021

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy.

Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy.

Journal: Journal of hematology & oncology

Published: May 27, 2021

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.

Long-term activity of tandem CD19/CD20 CAR therapy in refractory/relapsed B-cell lymphoma: a single-arm, phase 1-2 trial.

Journal: Leukemia

Published: December 19, 2020

Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.

Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphoma.

Journal: Theranostics

Published: October 15, 2020

Showing 1-12 of 23

Last Updated: 09/26/2026